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Fig. 1. The changes of leucigenin-enhanced chemiluminescence
(LucCL) intensity were more significantly increased in the ascorbic
acid–treated group than in the control group of hemodialysis patients.
(1261.0 ± 401.9 vs. 77.4 ± 62.5, ∗P < 0.05).
acute administration of ascorbic acid in larger doses may
have potential hazards in generating larger amount of
free radicals.
The study has demonstrated that NO involves the dila-
tor mechanism of acetylcholine, while ascorbic acid still
has an insignificant dilator effect in the presence of L-
NMMA (compared with L-NMMA alone). Whether the
action of vitamin C promotes the bioactivity of endoge-
nous NO is not known here. Furthermore, acidification
was known to augment NO-mediated relaxation in rat
artery [4]. Large dose infusion of ascorbic acid, with low
pKa of 4.2, might overload the buffer system in the local
uremic vascular milieu. This dilator effect may act possi-
bly through the acidosis of the biologic system.
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Proteinuria dipstick test: Is it
time to change?
To the Editor: In their recent paper published in
Kidney International, Iseki et al [1] demonstrated that
proteinuria, assessed by dipstick urinalysis, is an inde-
pendent risk factor of end-stage renal disease (ESRD) in
a mass screening setting.
Sensitivity of dipstick for proteinuria is low (albumin
>250 mg/L), and the cost for each strip is United States
dollars $0.71. The correct evaluation of proteinuria re-
quires a timed urine collection or, alternatively, the use of
the protein:creatinine ratio (P/C) on spot-morning urine
[2, 3]; the cost of reagents for P/C is United States dollars
$0.34.
We compared the data obtained from the analysis of
24-hour proteinuria, of the P/C, and of the dipstick test
in 297 patients with different kidney diseases, proteinuric
or not. We found a good correlation between the values
of 24-hour proteinuria and P/C (R = 0.82), and a lower
correlation between 24-hour proteinuria and dipstick test
(R = 0.75), and between P/C and dipstick test (R = 0.72).
In 54 patients (18.2%) the dipstick resulted negative; by
contrast, both of the other methods showed a pathologic
proteinuria.
In our experience the P/C is a reliable estimation of the
24-hour proteinuria, more sensitive than dipstick.
We conclude that P/C is a feasible, sensitive, low in cost,
simple test. Actually, in industrialized countries, this test
should be considered for a mass health screening in order
to detect early signs of ESRD and to allow appropriate
renoprotective treatments [4].
Furthermore, the P/C should be performed routinely
in selected settings for detecting low increases of protein-
uria otherwise not revealed by dipstick test.
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Reply from the Authors
We appreciate the comments from Dr. Gai et al con-
cerning the method of detecting proteinuria. A major
finding of our paper was that the degree of proteinuria
shown by dipstick urinalysis was strong as a predictor of
developing end-stage renal disease (ESRD) [1]. We have
recently analyzed the effect of blood pressure on devel-
oping ESRD in the same registry [2]. Comparing the two
papers, we learned that the relative strength of the degree
of dipstick proteinuria (−) to (1+) was similar to that of
different levels of blood pressure. Therefore, slight pro-
teinuria from (±) to 1+ is equally important as that of
mild to moderate hypertension. Although the cumula-
tive incidence of ESRD was low as less than 10 per 1000
screenees in 17 years.
The mass-screening registry, which was done in 1983
used the dipstick urine test (Ames) for detecting protein-
uria. We admit that the sensitivity of dipstick for protein-
uria is lower than that of measuring the protein:creatinine
(P/C) ratio. However, this method was not fully estab-
lished during the early 1980s. In Japan, public support
for the dipstick urine test was started in 1974 for ele-
mentary and junior high school students [3]. There is no
evidence to prove the utility of urine test for preventing
either ESRD or the urinary tract malignancies by mass
screening [4]. According to the 2001 annual report of the
Japanese Society for Dialysis Therapy, the mean age at
start of dialysis was 63.8 years, and the acceptance rate
was more than 250 per million population [5]. Chronic
glomerulonephritis as a primary cause of ESRD has not
increased since 1995. We believe that widespread use of
a screening test from school children to aged popula-
tion may have played a role, at least partly, in this phe-
nomenon. Screenees with dipstick positive proteinuria
(≥2+) are at high risk of developing ESRD [1].
The current cost of dipstick urine test, including both
proteinuria and other tests such as hematuria, ketones,
glucosuria, specific gravity, and pH, is 280 yen ($2.3
United States dollars) in Japan.
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Where have all the lanthanum
salts gone, long time passing?
To the Editor: The D’Haese study [1] should be reas-
suring that one-year treatment of lanthanum carbonate
heals bone diseases in dialysis patients.
However, no comparison is made between plasma lan-
thanum in the two groups of patients (lanthanum- or
calcium-treated), as it is only written that “patients on the
lanthanum group had plasma lanthanum levels slightly in-
creased, with mean levels ranging from 0.51 to 1.08 lg/L,”
and there was no relationship to the “dose administered.”
However, in previous works this “slight increase” was
10 to 25 times higher, from baseline 0.014 to 0.030 lg/L
to 0.346 to 0.776 lg/L, in a dose-dependent fashion
(Table 1), indicating the “existence of some degree of
intestinal absorption.” [2]
Lastly, the sentence “ . . . plasma lanthanum levels
reached a plateau after 12 weeks” is worrying. Where
has lanthanum gone? If biliary excretion is not greatly
increased (to be demonstrated), it accumulates into tis-
sues. The authors wrote that “in light of the past tragic
experience with aluminium . . . information on the effect
of lanthanum carbonate on bone is necessary,” but they
concluded that the five-fold increase in patient bone as
compared with control (after one only year) is not of
Table 1. Blood lanthanum levels increase in a dose-dependent
fashion in the lanthanum group at the end of a 6-week period
treatment in dialysis patientsa
Placebo group (N = 32) Lanthanum group (N = 113)
Lanthanum Blood lanthanum Lanthanum Blood lanthanum
carbonate levels at the carbonate levels at the
dose end of the study dose end of the study
mg/day lg/L mg/day lg/L
0 0.10 ± 0.23 225 0.23 ± 0.23
675 0.80 ± 1.18
1350 0.48 ± 0.43
2250 1.16 ± 1.91
aFrom Joy MS, Hladick G, Finn WF, and the Lanthanum Study Group: Safety
of an investigational phosphate binder lanthanum carbonate in haemodialysis
patients. Poster presented at the American Society Nephrology, Miami, Florida,
November, 1999. J Am Soc Nephrol 10:263A, 1999.
